Search
Intellia Therapeutics Inc
NTLAAdd to Watchlist
10.680USD
-0.410-3.70%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.49BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Intellia Therapeutics Inc is 7.05, ranking 311 out of 385 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 106.00 and a low of 4.00.
Analyst Rating
Based on
19
analysts
Hold
Current Rating
27.250
Target Price
+155.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Intellia Therapeutics Inc
NTLA
19
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Intellia Therapeutics Inc's expected revenue for the next quarter?
Intellia Therapeutics Inc's expected revenue is 13.90M.
What is Intellia Therapeutics Inc's price target?
Analysts forecast that Intellia Therapeutics Inc's price target is USD 14.00, with the highest forecast at USD 106.00 and the lowest forecast at USD 4.00.
How have Intellia Therapeutics IncNTLA's recent earnings per share performed?
The market expectation was USD -0.81, while Intellia Therapeutics IncNTLA's earnings per share (EPS) for the previous quarter was USD -0.83. EPS for the next quarter is expected at USD -0.80.
What is the analyst rating for Intellia Therapeutics Inc?
Based on the ratings of Intellia Therapeutics Inc's stock from 19 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.